高级搜索

晚期前列腺腺泡腺癌中c-MET表达与临床病理特征及预后的相关性

何伟莹, 孙文佳, 李慧瑜, 张杨鸽龄, 吴德, 敖春霞, 王锦程, 杨亚楠, 肖雪雪, 张璐瑶, 王曦源, 岳君秋

何伟莹, 孙文佳, 李慧瑜, 张杨鸽龄, 吴德, 敖春霞, 王锦程, 杨亚楠, 肖雪雪, 张璐瑶, 王曦源, 岳君秋. 晚期前列腺腺泡腺癌中c-MET表达与临床病理特征及预后的相关性[J]. 肿瘤防治研究. DOI: 10.3971/j.issn.1000-8578.2025.25.0041
引用本文: 何伟莹, 孙文佳, 李慧瑜, 张杨鸽龄, 吴德, 敖春霞, 王锦程, 杨亚楠, 肖雪雪, 张璐瑶, 王曦源, 岳君秋. 晚期前列腺腺泡腺癌中c-MET表达与临床病理特征及预后的相关性[J]. 肿瘤防治研究. DOI: 10.3971/j.issn.1000-8578.2025.25.0041
Wei-ying HE, Wen-jia SUN, Hui-yu LI, Yang-geLing ZHANG, De WU, Chun-xia AO, Jin-cheng WANG, Ya-nan YANG, Xue-xue XIAO, Lu-yao ZHANG, Xi-yuan WANG, Jun-qiu YUE. Analysis of the Correlation between c-MET Expression and Clinical Pathological Features and Prognosis in Advanced Prostatic Acinar Adenocarcinoma[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.2025.25.0041
Citation: Wei-ying HE, Wen-jia SUN, Hui-yu LI, Yang-geLing ZHANG, De WU, Chun-xia AO, Jin-cheng WANG, Ya-nan YANG, Xue-xue XIAO, Lu-yao ZHANG, Xi-yuan WANG, Jun-qiu YUE. Analysis of the Correlation between c-MET Expression and Clinical Pathological Features and Prognosis in Advanced Prostatic Acinar Adenocarcinoma[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.2025.25.0041

晚期前列腺腺泡腺癌中c-MET表达与临床病理特征及预后的相关性

基金项目: (2021-21-15)2021年吴阶平医学基金会临床科研专项资助基金No. 320.6750.

Analysis of the Correlation between c-MET Expression and Clinical Pathological Features and Prognosis in Advanced Prostatic Acinar Adenocarcinoma

  • 摘要: 目的 探讨c-MET在晚期前列腺腺泡腺癌患者中的表达与临床病理学参数及预后的相关性。方法 纳入湖北省肿瘤医院于2019年至2023年间收治的135名晚期前列腺腺泡腺癌患者标本。通过免疫组化(IHC)检测c-MET蛋白表达,荧光原位杂交(FISH)检测c-MET基因扩增,分析c-MET蛋白表达及基因扩增状况与临床病理学参数及预后的相关性。结果 c-MET阳性表达率为52.60%(71/135)。与癌旁正常组织相比,c-MET在肿瘤中呈现较低的异质性表达。1.71%(2/117)病例存在 c-MET基因多倍体,未检测出c-MET扩增。c-MET蛋白的阳性表达与更高的Gleason评分/分级分组显著相关(P=0.0073)。然而,c-MET的表达与无进展生存期(PFS)或治疗后t-PSA水平无显著相关。结论 c-MET在晚期前列腺腺泡腺癌中表达水平较低,可能不适于前列腺腺泡腺癌的ADC药物开发。

     

    Abstract: Objective: The aim of this study was to investigate the expression of c-MET in patients with advanced prostatic acinar adenocarcinoma and its potential correlation with clinicopathological parameters and prognosis. Methods: A cohort of 135 patients with advanced prostatic acinar adenocarcinoma who were treated at Hubei Cancer Hospital between 2019 and 2023 was included in the study. Immunohistochemistry (IHC) was utilized to assess c-MET protein expression in tumor tissues, while fluorescence in situ hybridization (FISH) was employed to evaluate c-MET gene amplification. The relationships of c-MET expression and gene amplification with clinicopathological features and prognosis were analyzed. Results: The positive expression rate of c-MET in this patient cohort was 52.60% (71/135). In comparison to adjacent normal tissues, c-MET expression in tumor tissues showed lower heterogeneous expression. Among the cases, 1.71% (2/117) exhibited c-MET gene polyploidy, but no gene amplification was detected. Positive c-MET expression was significantly correlated with higher Gleason scores and grade groups (P=0.0073). However, no significant relationship was found between c-MET expression and progression-free survival (PFS) or post-treatment t-PSA levels. Conclusion: c-MET is expressed at a relatively low level in advanced prostatic acinar adenocarcinoma, suggesting that c-MET may not be a viable target for ADC drugs development in prostatic acinar adenocarcinoma.

     

计量
  • 文章访问数:  334
  • HTML全文浏览量:  57
  • PDF下载量:  83
  • 被引次数: 0
出版历程
  • 收稿日期:  2025-01-13
  • 修回日期:  2025-03-25
  • 录用日期:  2025-04-20
  • 网络出版日期:  2025-04-21

目录

    /

    返回文章
    返回
    x 关闭 永久关闭